FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.17
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$30.68

08 Jun
2026

0.000

OPEN

$30.68

0.000

HIGH

$30.68

0

LOW

$30.68

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) 79.1 xxx
DPS (cps) 50.4 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 39.7 xxx
Dividend Yield 1.6% xxx
Div Pay Ratio(%) 63.8% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/12 - (franking ex-div 22.35c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx70.9
DPS All xxxxxxxxxxxxxxx54.4
Sales/Revenue xxxxxxxxxxxxxxx2,078.4 M
Book Value Per Share xxxxxxxxxxxxxxx300.2
Net Operating Cash Flow xxxxxxxxxxxxxxx589.3 M
Net Profit Margin xxxxxxxxxxxxxxx20.03 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx23.93 %
Return on Invested Capital xxxxxxxxxxxxxxx22.90 %
Return on Assets xxxxxxxxxxxxxxx17.73 %
Return on Equity xxxxxxxxxxxxxxx23.93 %
Return on Total Capital xxxxxxxxxxxxxxx31.69 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx211.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx27 M
Long Term Debt xxxxxxxxxxxxxxx94 M
Total Debt xxxxxxxxxxxxxxx122 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx384 M
Price To Book Value xxxxxxxxxxxxxxx10.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx173.5 M
Capex % of Sales xxxxxxxxxxxxxxx8.35 %
Cost of Goods Sold xxxxxxxxxxxxxxx745 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx741 M
Research & Development xxxxxxxxxxxxxxx209 M
Investments - Total xxxxxxxxxxxxxxx36 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

27/05/2026

3

Neutral

-

-

Following yesterday's relief rally, UBS believes Fisher & Paykel Healthcare's share price fairly reflects slightly lower medium-term EPS growth and higher sector risk profile.

Hospital consumable outlook remains robust however Homecare growth is lower with delays to new OSA mask releases, and margin headwinds from higher resins/plastics and distribution costs.

UBS does not see a material PE re-rating from 40x given the record premium to A&NZ large-cap healthcare peers, and risk from extra US medical device tariffs. Neutral retained, target rises to NZ$37.50 from NZ$35.30.

FORECAST
UBS forecasts a full year FY27 dividend of 52.06 cents and EPS of 78.97 cents.
UBS forecasts a full year FY28 dividend of 61.61 cents and EPS of 92.85 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

12/05/2026

3

Neutral

-

-

Jarden maintains a Neutral rating for Fisher & Paykel Healthcare and lowers the target price to NZ$39.50 from NZ$40.20 ahead of the upcoming full-year results release.

A strong finish to FY26 is anticipated, with hospital product demand outperforming expectations due to structural changes in clinical practice rather than seasonal flu variations.

Near-term volatility is expected as maiden FY27 guidance must navigate higher oil-based feedstock inflation, elevated freight rates linked to Middle East disruptions, and an evolving US tariff regime.

Despite these external cost headwinds, the clinical evidence pipeline remains robust, supporting ongoing medium-term growth prospects across new hospital applications.

Adjusting for these cost pressures and higher risk-free rates, earnings per share estimates have been revised to NZ80.9c from NZ80.7c in FY26, to NZ90.8c from NZ92.9c in FY27, and to NZ104.6c from NZ105.7c in FY28.

FORECAST
Jarden forecasts a full year FY27 EPS of 78.79 cents.
Access Extra Coverage Research History >

FPH STOCK CHART

FNArena News on FPH

1
Rudi’s View: Australia’s Sh*t Sandwich

Jun 04 2026 - Rudi's View
2
FNArena Corporate Results Monitor – 01-06-2026

Jun 01 2026 - Australia
3
Australian Broker Call *Extra* Edition – May 28, 2026

May 28 2026 - Daily Market Reports
4
Rudi’s View: AI Is Making A Come-Back

May 13 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – May 12, 2026

May 12 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
2
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
3
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
4
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
5
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
6
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
7
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
8
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
9
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
10
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia